Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REL-1017 as Adjunctive Treatment of Major Depressive Disorder
NCT04855747Phase 3Terminated
- Sponsor
- Levomecor
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esmethadone in major depressive disorder (MDD), sponsored by Levomecor. Started Mar 2021; status: terminated.
02
Drugs
esmethadone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04855747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855747.